Loading clinical trials...
Loading clinical trials...
A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9)
Conditions
Interventions
Loncastuximab Tesirine
Rituximab
Locations
41
United States
University of Arizona Cancer Center
Tucson, Arizona, United States
Winthrop P. Rockefeller Cancer Institute
Little Rock, Arkansas, United States
Rocky Mountain Cancer Centers - Aurora
Aurora, Colorado, United States
USOR - Illinois Cancer Specialists - Niles
Niles, Illinois, United States
Leonard Lawson Cancer Center
Pikeville, Kentucky, United States
Cancer Care Specialists - Nevada
Reno, Nevada, United States
Start Date
June 21, 2022
Primary Completion Date
January 22, 2024
Completion Date
January 22, 2024
Last Updated
January 30, 2025
NCT05139017
NCT01804686
NCT07443514
NCT05755087
NCT04739813
NCT06785818
Lead Sponsor
ADC Therapeutics S.A.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions